| Title: | A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2) |
| Authors: | Nomoto, H. Browse this author |
| Miyoshi, H. Browse this author →KAKEN DB |
| Furumoto, T. Browse this author |
| Oba, K. Browse this author |
| Tsutsui, H. Browse this author |
| Miyoshi, A. Browse this author |
| Kondo, T. Browse this author |
| Tsuchida, K. Browse this author |
| Atsumi, T. Browse this author |
| Manda, N. Browse this author |
| Kurihara, Y. Browse this author |
| Aoki, S. Browse this author |
| SAIS Study Group Browse this author |
| Issue Date: | Apr-2016 |
| Publisher: | World Biomedical Frontiers |
| Citation: | World Biomedical Frontiers |
| Abstract: | Objective: Glucagon-like peptide-1 (GLP-1) improves hyperglycemia, and it has been reported to have favorable effects on atherosclerosis. However, it has not been fully elucidated whether GLP-1 is able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of the GLP-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy. Materials and Methods: In this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8 %) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks. Flow mediated dilatation (FMD), a comprehensive panel of hemodynamic parameters (Task Force Monitor), and serum metabolic markers were assessed before and after the treatment period. Results: A greater reduction (worsening) in %FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4 %, glargine 6.7 to 5.7 %). The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group. Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early liraglutide therapy did not affect endothelial function but may provide favorable effects on beta-cell function and cardioprotection in type 2 diabetics without advanced atherosclerosis. |
| Relation: | http://biomedfrontiers.org/diabetes-obesity-2016-16/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/68417 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
